JTT 651Alternative Names: JTT-651
Latest Information Update: 23 Jul 2009
At a glance
- Originator Japan Tobacco
- Mechanism of Action Glycogen phosphorylase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Type 2 diabetes mellitus
Most Recent Events
- 31 Mar 2009 Discontinued - Phase-I for Type-2 diabetes mellitus in Japan (PO)
- 09 Aug 2007 Phase-I clinical trials in Type-2 diabetes mellitus in Japan (PO)